Twist Bioscience Corporation
TWSTHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframePart of the healthcare sector, Twist Bioscience Corporation (TWST) is listed under Biotechnology. With a market capitalization of $9.28B, it sits in mid-cap territory. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Market Cap
$9.28B
Beta
2.19
P/E (TTM)
—
P/E (Fwd)
-349.80
EPS (TTM)
$-2.23
EPS (Fwd)
$-0.40
ROE
-29.6%
ROA
-13.1%
Cash
$166.8M
Total Debt
$108.6M
Free CF
-$64.8M
52W Change
309.4%
Annual Financials
Cash vs Debt
Where TWST stands vs its 150-day and 200-day moving averages
As of the October 12, 2026 close, TWST finished 72.07% above its 150-day moving average ($92.86) and 98.63% above its 200-day moving average ($80.44). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TWST overbought or oversold?
At the October 12, 2026 close, TWST's RSI(14) was 47.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $166.8M in cash comfortably exceeding the $108.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$64.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -29.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $203.6M (2022) to $376.6M (2025), reflecting a 85% increase over the period.
Twist Bioscience Corporation's elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing TWST's risk profile alongside its fundamentals and technical indicators provides a more complete picture.